Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 175

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 175
---
 Rule 144 are also limited by manner of sale provisions and notice requirements and by the availability of current public information about Revelation. 111 SECURITY OWNERSHIP OF MANAGEMENT AND CERTAIN BENEFICIAL OWNERS The following table also sets forth information known to us regarding the beneficial ownership of our Common Stock as of May 21, 2025:

| ● | each person who is, or is expected to be, the beneficial             
 owner of more than 5% of the outstanding shares of our Common Stock; |

| ● | each of our current officers and directors; and |

| ● | all current executive officers and directors of the Company, 
 as a group.                                                  |

Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. Shares of Common Stock issuable pursuant to options or warrants are deemed to be outstanding for purposes of computing the beneficial ownership percentage of the person or group holding such options or warrants but are not deemed to be outstanding for purposes of computing the beneficial ownership percentage of any other person. The beneficial ownership of our Common Stock is based on 963,796 shares of Common Stock issued and outstanding as of May 21, 2025. Unless otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all shares of common stock owned by them.

| Name                                                    |     | Number of    
 Shares       
 Beneficially 
 Owned        |        |     | Beneficial 
 Ownership  
 (%)        |     |   |
| Directors and Officers of Revelation(1):                |     |              |        |     |            |     |   |
| James Rolke(2)                                          |     |              | 30,142 |     |            | 3.2 | % |
| George F. Tidmarsh M.D., Ph.D.(3)                       |     |              |    281 |     |            |   * |   |
| Jennifer Carver, BSN, MBA(4)                            |     |              |    200 |     |            |   * |   |
| Jess Roper(5)                                           |     |              |    196 |     |            |   * |   |
| Lakhmir Chawla, M.D.(6)                                 |     |              |